Stay updated on XmAb20717 Safety & Efficacy in Rare Cancers Clinical Trial
Sign up to get notified when there's something new on the XmAb20717 Safety & Efficacy in Rare Cancers Clinical Trial page.

Latest updates to the XmAb20717 Safety & Efficacy in Rare Cancers Clinical Trial page
- CheckyesterdayChange DetectedAn added revision note (v3.3.3) and the removal of the HHS Vulnerability Disclosure, along with a prior revision note (v3.3.2), are administrative updates to the page footer; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.3.2 appears in the page header, replacing Revision: v3.3.1. Other study details and navigation are unchanged.SummaryDifference0.1%

- Check29 days agoChange DetectedAdded Revision: v3.3.1 to the record history and removed Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedDeleted the site-wide notice about government funding lapse and NIH operating status that previously appeared on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check51 days agoChange DetectedOld and New screenshots show the same Record History page with minor visual differences and no new data or status changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedAdded new date references and a study-status/oversight label (IPDSharing); removed an earlier date. Overall, a minor update to project/status information rather than core content.SummaryDifference1%

Stay in the know with updates to XmAb20717 Safety & Efficacy in Rare Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XmAb20717 Safety & Efficacy in Rare Cancers Clinical Trial page.